Notably, we showed that Alphataxin, as monotherapy, increased the number of CD4+ TILs and suppressed tumor growth, and when combined with anti-PD-1 immunotherapy, significantly suppressed or regressed tumor growth. The gene discussed is CD4; the disease is neoplasm.